Amneal Pharmaceuticals and Bial announced a licensing agreement where Amneal will have exclusive rights to market and distribute Ongentys in the U.S. starting on December 18. Amneal expects to begin distribution of Ongentys in early 2024. The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $6 from $5 at Barclays
- Amneal Pharmaceuticals raises 2023 adjusted EPS view to 51c-58c from 45c-55c
- Amneal Pharmaceuticals reports Q3 adjusted EPS 19c, consensus 11c
- Amneal Pharmaceuticals rises 17.2%
- Amneal Pharmaceuticals raises FY23 EPS view to 51c-58c from 45c-55c